Atara Biotherapeutics, Inc.ATRAEarnings & Financial Report
Atara Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic T-cell immunotherapies for patients with unmet medical needs across oncology, autoimmune disease, and infectious disease indications. It operates primarily in North America, Europe, and Asia-Pacific, partnering with research institutions to advance its novel treatment pipeline.
Revenue
$3.5M
Gross Profit
N/A
Operating Profit
$-3.6M
Net Profit
$-4.3M
Gross Margin
N/A
Operating Margin
-103.5%
Net Margin
-124.6%
YoY Growth
-91.4%
EPS
$-0.32
Atara Biotherapeutics, Inc. Q3 FY2025 Financial Summary
Atara Biotherapeutics, Inc. reported revenue of $3.5M (down 91.4% YoY) for Q3 FY2025, with a net profit of $-4.3M (up 80.4% YoY) (-124.6% margin).
Key Financial Metrics
| Total Revenue | $3.5M |
|---|---|
| Net Profit | $-4.3M |
| Gross Margin | N/A |
| Operating Margin | -103.5% |
| Report Period | Q3 FY2025 |
Atara Biotherapeutics, Inc. Annual Revenue by Year
Atara Biotherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $120.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $120.8M |
| 2024 | $128.9M |
| 2023 | $8.6M |
| 2022 | $63.6M |
Atara Biotherapeutics, Inc. Quarterly Revenue & Net Profit History
Atara Biotherapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.6M | -95.1% | N/A | N/A |
| Q3 FY2025 | $3.5M | -91.4% | $-4.3M | -124.6% |
| Q2 FY2025 | $17.6M | -38.6% | $2.4M | 13.6% |
| Q1 FY2025 | $98.1M | +258.8% | $38.0M | 38.7% |
| Q4 FY2024 | $32.8M | +670.3% | $-12.7M | -38.8% |
| Q3 FY2024 | $40.2M | +1779.8% | $-21.9M | -54.5% |
| Q2 FY2024 | $28.6M | +2892.7% | $-19.0M | -66.5% |
| Q1 FY2024 | $27.4M | +2131.4% | $-31.8M | -116.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $27.4M | $28.6M | $40.2M | $32.8M | $98.1M | $17.6M | $3.5M | $1.6M |
| YoY Growth | 2131.4% | 2892.7% | 1779.8% | 670.3% | 258.8% | -38.6% | -91.4% | -95.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $165.3M | $117.3M | $142.7M | $109.1M | $62.0M | $36.9M | $30.2M | $20.2M |
| Liabilities | $263.6M | $228.2M | $233.2M | $206.4M | $117.1M | $71.9M | $66.8M | $58.7M |
| Equity | $-98.3M | $-110.9M | $-90.5M | $-97.3M | $-55.1M | $-35.0M | $-36.6M | $-38.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-29.6M | $-10.6M | $-4.0M | $-24.5M | $-28.1M | $-7.3M | $-9.8M | $-50.9M |